Larimar Therapeutics, Inc.
NASDAQ: LRMR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carole S. Ben-Maimon
- Employees
- 65
- Headquarters
- Bala Cynwyd, United States
- IPO year
- 2014
- Market cap
- $310.6M
- Website
- https://www.larimartx.com
Loading LRMR…
Loading profile data…Frequently asked questions about LRMR
What does Larimar Therapeutics, Inc. (LRMR) do?
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clini...
Where does LRMR trade?
Larimar Therapeutics, Inc. (LRMR) trades on the NASDAQ Global Market.
What sector is LRMR in?
Larimar Therapeutics, Inc. (LRMR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Larimar Therapeutics, Inc.?
Carole S. Ben-Maimon is the chief executive officer of Larimar Therapeutics, Inc. (LRMR).
Where is Larimar Therapeutics, Inc. headquartered?
Larimar Therapeutics, Inc. is headquartered in United States.
Does LRMR pay a dividend?
Larimar Therapeutics, Inc. (LRMR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LRMR go public?
Larimar Therapeutics, Inc. (LRMR) completed its initial public offering in 2014.